Literature DB >> 18308651

Compliance and persistence in pediatric and adult patients receiving growth hormone therapy.

Ron G Rosenfeld1, Bert Bakker.   

Abstract

OBJECTIVE: To identify key factors that influence compliance and persistence in patients receiving growth hormone (GH) therapy and to promote the development of interventions to support continuous GH use.
METHODS: A 134-question survey was conducted involving 158 adult patients, 326 adolescents or teens, and 398 parents of children currently receiving or previously treated with GH. Questions explored perceptions about GH deficiency and treatment outcomes, quality of training received for administration of injections, and disruptions affecting compliance and persistence with therapy. Compliance was defined by a categorical assessment of frequency of missed GH doses for specific reasons. Persistence was defined as continuing GH therapy with no interruption.
RESULTS: On the basis of their responses to questions about potential reasons for missing GH doses, patients were categorized by level of compliance into 3 segments--highly compliant, occasionally noncompliant, or noncompliant and skeptical. Noncompliance with GH therapy (that is, classification in one of the last 2 segments) ranged from 64% to 77% among the 3 age-groups evaluated, with teens having the highest rate of noncompliance. Misperceptions about the consequences of missed GH doses, discomfort with injections, dissatisfaction with treatment results, and inadequate contact with health-care providers (along with other factors) were strongly associated with noncompliance. Survey questions related to these factors were considered useful for identifying patients requiring additional support or intervention to improve compliance.
CONCLUSION: Routine education should emphasize therapeutic end points and their relationship to compliance with GH therapy in an effort to convince and empower patients with GH deficiency to use self-care strategies to achieve their treatment goals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308651     DOI: 10.4158/EP.14.2.143

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  58 in total

1.  Long-acting growth hormone.

Authors:  Charlotte Höybye; Jens Sandahl Christiansen
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

2.  Efficacy and safety of long-acting growth hormone in children with short stature: a systematic review and meta-analysis.

Authors:  Yingying Yang; Xi Bai; Xianxian Yuan; Yuelun Zhang; Shi Chen; Hongbo Yang; Hanze Du; Huijuan Zhu; Hui Pan
Journal:  Endocrine       Date:  2019-05-22       Impact factor: 3.633

Review 3.  Perspectives on long-acting growth hormone therapy in children and adults.

Authors:  Rayhan A Lal; Andrew R Hoffman
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

4.  Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.

Authors:  Tao Liu; Yong Zhang; Yan Liu; Ying Wang; Haiqun Jia; Mingchao Kang; Xiaozhou Luo; Dawna Caballero; Jose Gonzalez; Lance Sherwood; Vanessa Nunez; Danling Wang; Ashley Woods; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

5.  12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency.

Authors:  Beverly M K Biller; Hyi-Jeong Ji; Hyunji Ahn; Conrad Savoy; E Christine Siepl; Vera Popovic; Mihail Coculescu; Josefine Roemmler; Catalin Gavrila; David M Cook; Christian J Strasburger
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

6.  Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope®: a questionnaire-based observational study conducted in paediatric patients in France.

Authors:  Régis Coutant; Clémentine Dupuis; Patricia Pigeon; Phillipe Rebaud
Journal:  Ther Adv Endocrinol Metab       Date:  2017-10-02       Impact factor: 3.565

7.  A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.

Authors:  Wayne V Moore; Huong Jil Nguyen; Gad B Kletter; Bradley S Miller; Douglas Rogers; David Ng; Jerome A Moore; Eric Humphriss; Jeffrey L Cleland; George M Bright
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

8.  Long-Acting Growth Hormone Preparations in the Treatment of Children.

Authors:  Rayhan A Lal; Andrew R Hoffman
Journal:  Pediatr Endocrinol Rev       Date:  2018-09

Review 9.  Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.

Authors:  Bradley S Miller; Eric Velazquez; Kevin C J Yuen
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 10.  Individual sensitivity to growth hormone replacement in adults.

Authors:  Cesar Luiz Boguszewski
Journal:  Rev Endocr Metab Disord       Date:  2020-10-07       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.